We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mutation That Induces High Blood Pressure in Women Linked to Increased Heart Attack Risk

By LabMedica International staff writers
Posted on 05 Aug 2014
A mutation in women in the G-protein coupled estrogen receptor 30 (GPER) gene generates a receptor with reduced activity that induces high blood pressure, the single biggest risk factor for heart attack and stroke.

The GPER gene is a member of the G-protein coupled receptor 1 family and encodes an integral membrane protein with high affinity for estrogen that localizes to the endoplasmic reticulum. More...
The protein binds estrogen, resulting in intracellular calcium mobilization and synthesis of phosphatidylinositol 3,4,5-trisphosphate in the nucleus. This protein plays a role in the rapid nongenomic signaling events widely observed following stimulation of cells and tissues with estrogen.

Investigators at the Schulich School of Medicine & Dentistry (London, ON, Canada) found that a common missense genetic variant of GPER, P16L GPER, was poorly functional when expressed in vascular smooth muscle cells. Furthermore, females—but not males—carrying this genetic variant had increased blood pressure and had a higher allelic prevalence in a highly selected population of hard-to-treat hypertensive patients.

"This is one step in understanding the effects of estrogen on heart disease, and understanding why some women are more prone to heart attack and stroke than others," said senior author Dr. Ross Feldman, professor of medicine and physiology/pharmacology at the Schulich School of Medicine & Dentistry. "Our work is a step forward in developing approaches to treating heart disease in this under-appreciated group of patients."

The study was published in the July 21, 2014, online edition of the British Journal of Clinical Pharmacology.

Related Links:

Schulich School of Medicine & Dentistry



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.